Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with chemotherapy and bevacizumab in cervical neuroendocrine carcinoma
NCT04635956Phase 2Unknown
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in cervical neuroendocrine carcinoma (NECC). Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
cervical neuroendocrine carcinoma (NECC)
Beyond the preview
Go deeper on NCT04635956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635956.